Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
NCT06831058Phase 2Recruiting
- Sponsor
- University of Minnesota
- Start
- May 2025
- Primary completion
- May 2028
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa in thrombotic thrombocytopenic purpura (TTP), sponsored by University of Minnesota. Primary endpoints: Incidence of relapse, Safety and tolerability of efgartigimod compared to historical rituximab arm and 2 more. Started May 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT06831058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06831058.